The results of the clinical studies of Imeglimin in patients with type 2 diabetes mellitus demonstrated the promising efficacy of Imeglimin both in monotherapy and combination therapies and indicated its acceptable safety. Based on these results, the proposed indication of "type 2 diabetes mellitus" is acceptable.
The product is not classified
Imeglimin's mechanism of action involves dual effects: (a) amplification of glucose-stimulated insulin secretion (GSIS) and preservation of β-cell mass; and (b) enhanced insulin action, including the potential for inhibition of hepatic glucose output and improvement in insulin signalling in both liver and skeletal muscle. At a cellular and molecular level, Imeglimin's underlying mechanism may involve correction of mitochondrial dysfunction, a common underlying element of T2D pathogenesis. It has been observed to rebalance respiratory chain activity (partial inhibition of Complex I and correction of deficient Complex III activity), resulting in reduced reactive oxygen species formation (decreasing oxidative stress) and prevention of mitochondrial permeability transition pore opening (implicated in preventing cell death). In islets derived from diseased rodents with T2D, Imeglimin also enhances glucose-stimulated ATP generation and induces the synthesis of nicotinamide adenine dinucleotide (NAD+) via the 'salvage pathway'. In addition to playing a key role as a mitochondrial co-factor, NAD+ metabolites may contribute to the increase in GSIS (via enhanced Ca++ mobilization). Imeglimin has also been shown to preserve β-cell mass in rodents with T2D. Overall, Imeglimin appears to target a key root cause of T2D: defective cellular energy metabolism. This potential mode of action is unique and has been shown to differ from that of other major therapeutic classes, including biguanides, sulphonylureas and glucagon-like peptide-1 receptor agonists.
The usual adult dosage is 1000 mg of Imeglimin Hydrochloride administered orally twice daily in the morning and evening.
Contraindications
Imeglimin tablets are contraindicated in patients with:
Hypersensitivity to the drug or any of its components.
Severe ketosis, diabetic coma or pre-coma and also for immediate remedy in type 1 diabetes of hyperglycemias with infusion and insulin. This medicine may cause hypoglycemic symptoms. Therefore pay close attention while working at heights, drive a car, or operate dangerous machinery.
If hypoglycemic symptoms occur, take sugar-containing foods or sugar. If you are taking alfa-glucosidase inhibitor (acarbose, voglibose, miglitol) in combination with this medicine, take glucose.
Dosage reduction might be required for patients with renal impairment, eGFR<15 ml/min/1.73 m2
The most commonly reported side effects include nausea, diarrhea and constipation. Weakness, hungry feeling, sweating (hypoglycaemia) may also occur.
Pregnancy: The safety of this product in pregnant women has not been established. Imeglimin should be used in pregnant women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment.
Lactation: Breast-feeding must be discontinued during administration of this product in lactating women (transfer to milk in animal studies has been reported).
In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy if required.
Store in a cool (below 30°C) & dry place protected from the light. Keep away from the reach of children.
.png&w=384&q=75)